Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020 - JCN Newswire

German Federal Regulator Confirms Additional Benefit of Anti-cancer Agent Halaven(R) for Metastatic or Locally Advanced Breast Cancer (Apr 23, 2012) Abbott Japan and Eisai have Cleared the Condition for Approval of Humira(R), a Fully Human Anti-TNF-Alpha ...

Research and Markets: Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Yahoo Finance

All of the novel targeted therapies (Votrient (pazopanib) in 2014, TH-302 in 2015, Yondelis (trabectedin) and Halaven (eribulin mesylate) in 2016) are also expected to be launched in the forecast period. These will replace the existing off-label ...

Researchers Looking for Drug Candidates Tap into the Final Frontier: The Sea - Genetic Engineering News

Developing novel drugs from sea creatures takes tremendous resources. It took about 17 years to discover and develop the breast cancer drug Halaven, approved by the FDA in 2010, Ted Suh, Ph.D., senior director, lead identification at Eisai’s ...

Celldex Targeted Drug Shrinks Breast Cancer - Inside Fidelity

About half of the patients in the CDX-011 study were treated with either Halaven or Ixempra. Neither drug was able to shrink tumors in patients who over-expressed GPNMB, said Celldex. The CDX-011 study is still ongoing so it's not known whether the drug ...

Is this a progression? - American Cancer Society

I don't know what to think anymore. We have been on chemo for 3 years straight. Eleventh round of HAlaven. I am scared that it may spread now. Is it possible? He was just increased to 125 mcg of fentanyl, 8 mg of dilaudid every 4 hours, and 2700 mg of ...

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab, Gemcitabine (Gemzar), Goserelin (Zoladex), Herceptin SC ...

Eisai : INC. EXPANDS MARKETING AND SUPPLY AGREEMENT WITH ARENA FOR ANTI-OBESITY AGENT LORCASERIN - 4-traders (press release)

In Canada, Eisai has commenced sales of the antiepileptic agent Banzel® as well as the chemotherapeutic implant Gliadel® Wafer for the treatment of certain malignant brain tumors and the anticancer agent Halaven®. 2.  About Lorcaserin Lorcaserin ...

Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting - PressePortal.de

Halaven(R) (eribulin) Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of patients with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy ...